A US court just put ownership of CRISPR back in play
1 min read
Summary
US Court of Appeals for the Federal Circuit has ruled that scientists Jennifer Doudna and Emmanuelle Charpentier will be given the opportunity to show they should own the key patents for CRISPR gene-editing technology.
The case relates to the use of CRISPR to edit inside animal cells and both parties say they were the first to conceive this aspect of the invention in 2012.
In 2022, a specialised body, the Patent Trial and Appeal Board, ruled that Doudna and Charpentier hadn’t fully conceived the invention.
However, the appeals court has now vacated this decision, stating that the patent board applied the wrong standard and must reconsider the case.
The Supreme Court could ultimately rule on the case.